Genesis of an IPO ... from NO

EDITOR'S NOTE: Carl Djerassi's novel NO concerns the development of a fictional, though close-to-life, drug and delivery system for the relief of male impotence. While the science in the novel is accurate, the book is a work of fiction. Nevertheless, some real-life characters, including Djerassi himself (a professor in the chemistry department at Stanford University), and other more or less disguised fictional characters based on real people make appearances in the book. In this issue and in t

Written byCarl Djerassi
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

EDITOR'S NOTE: Carl Djerassi's novel NO concerns the development of a fictional, though close-to-life, drug and delivery system for the relief of male impotence. While the science in the novel is accurate, the book is a work of fiction. Nevertheless, some real-life characters, including Djerassi himself (a professor in the chemistry department at Stanford University), and other more or less disguised fictional characters based on real people make appearances in the book. In this issue and in the upcoming October 26 issue, we are publishing Chapter 19. In this extract we meet the chief protagonist of the book, an Indian scientist named Renu Krishnan, who has developed a drug called NONO-2 and a delivery system called MUSA. Guided by Martin Gestler, a hard-charging expert on biotechnology start-up companies, she has left academic research to found a company called SURYA. The extract describes the preparation and launch of the fledgling company ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies